A longtime leader in healthcare improvement, we’re developing new ways to revolutionize the industry.
Watch this on-demand webinar for an overview of how the policies included in these final rules could impact your organization.
The PINC AI™ Applied Sciences team and their partners continue their work to develop long-lasting solutions to our nation’s health equity crisis.
Integrating PINC AI™ Clinical Surveillance technology in long-term care (LTC) facilities, enables early adverse drug event (ADE) detection and improved patient safety.
Premier recommends ways for FDA to incorporate emerging technologies into drug development and provide clarity for manufacturers.
Premier urges the DEA to ensure reductions in opioid manufacturing quotas do not exacerbate recent drug shortages.
PINC AI™ Applied Sciences is committed to advancing health equity through real-world, data-driven research and solutions co-designed with health systems and life sciences partners.
Life sciences companies need to invest in RWD/RWE as payers, regulatory bodies, and health systems demand proof that a medical solution delivers real value.
Builds on efforts to create healthier pharmaceutical markets that ensure continuous access and prevent shortages that can compromise patient care.
PM360 |
Data clearly matters in pharma. For the fourth year in a row AI and Big Data ranked as the most impactful technologies in the industry.
Watch this on-demand webinar for a deep dive into the current policy landscape around dementia care, including an overview of this new CMS Innovation Center...
Forbes |
From improving patient outcomes and easing clinicians’ workloads to advancing clinical trials and predicting supply shortages, AI is supporting better, smarter, faster healthcare.
Premier responds to CMS' final rule to compensate hospitals for past underpayments for 340B drugs.